• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Verrica Pharmaceuticals Inc. - Common Stock (NQ:VRCA)

    8.010 +0.860 (+12.03%)
    Streaming Delayed Price Updated: 11:13 AM EDT, May 13, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 22,385
    Open 6.910
    Bid (Size) 7.930 (100)
    Ask (Size) 8.240 (100)
    Prev. Close 7.150
    Today's Range 6.810 - 8.200
    52wk Range 3.280 - 9.821
    Shares Outstanding 41,957,197
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Verrica (VRCA) Q1 2026 Earnings Transcript ↗
    Verrica (VRCA) Q1 2026 Earnings Transcript 
    Via The Motley Fool
    News headline image
    Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire

    Performance

    YTD
    -3.5%
    -3.5%
    1 Month
    +42.5%
    +42.5%
    3 Month
    +32.8%
    +32.8%
    6 Month
    +118.9%
    +118.9%
    1 Year
    +58.2%
    +58.2%

    More News

    Read More
    News headline image
    Verrica Pharmaceuticals Q1 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    Verrica Pharmaceuticals (NASDAQ:VRCA) Q1 Results Beat Revenue Estimates as Pipeline Progress and Record Demand Drive Positive Momentum ↗
    Via Chartmill
    Verrica Pharmaceuticals Inc (NASDAQ:VRCA) Reports Q4 Earnings Beat and Accelerating Revenue Growth ↗
    Via Chartmill
    Topics Earnings
    News headline image
    Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    VRCA Investors Have the Opportunity to Join Investigation of Verrica Pharmaceuticals Inc. with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    News headline image
    VRCA Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA
    From The Rosen Law Firm, P.A.
    Via Business Wire
    News headline image
    Verrica Pharmaceuticals Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA
    From The Rosen Law Firm, P.A.
    Via Business Wire
    News headline image
    Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Which stocks are gapping on Monday? ↗
    Via Chartmill
    News headline image
    Top stock movements in today's session. ↗
    Via Chartmill
    News headline image
    Which stocks are moving on Friday? ↗
    Via Chartmill
    News headline image
    Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash Runway
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Verrica Pharmaceuticals Inc. - Common Stock publicly traded?
    Yes, Verrica Pharmaceuticals Inc. - Common Stock is publicly traded.
    What exchange does Verrica Pharmaceuticals Inc. - Common Stock trade on?
    Verrica Pharmaceuticals Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Verrica Pharmaceuticals Inc. - Common Stock?
    The ticker symbol for Verrica Pharmaceuticals Inc. - Common Stock is VRCA on the Nasdaq Stock Market
    What is the current price of Verrica Pharmaceuticals Inc. - Common Stock?
    The current price of Verrica Pharmaceuticals Inc. - Common Stock is 8.010
    When was Verrica Pharmaceuticals Inc. - Common Stock last traded?
    The last trade of Verrica Pharmaceuticals Inc. - Common Stock was at 05/13/26 11:13 AM ET
    What is the market capitalization of Verrica Pharmaceuticals Inc. - Common Stock?
    The market capitalization of Verrica Pharmaceuticals Inc. - Common Stock is 336.08M
    How many shares of Verrica Pharmaceuticals Inc. - Common Stock are outstanding?
    Verrica Pharmaceuticals Inc. - Common Stock has 336M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.